This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for BioCryst (BCRX) points to a 55.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Best Momentum Stocks to Buy for May 9th
by Zacks Equity Research
BCRX, WYY and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2025.
New Strong Buy Stocks for May 9th
by Zacks Equity Research
CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025.
Why BioCryst (BCRX) Might be Well Poised for a Surge
by Zacks Equity Research
BioCryst (BCRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for BioCryst (BCRX) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 100% and 14.97%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Inotiv (NOTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
BioCryst (BCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for BioCryst (BCRX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for BioCryst (BCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 84.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Company News for Feb 25, 2025
by Zacks Equity Research
Companies in The News Are: DPZ,WLK,BCRX,NFLX
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -116.67% and 0.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 0% and 2.01%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%
by Zacks Equity Research
The consensus price target hints at a 79.5% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BioCryst (BCRX) Upgraded to Buy: Here's Why
by Zacks Equity Research
BioCryst (BCRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for BioCryst (BCRX) points to a 99.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 68.42% and 11.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.